Evidence map›Paper›PMID 42399486›Full record

ReviewNature protocols2026

iMUT-seq mapping of DSB-induced mutations with high sensitivity at single-nucleotide resolution.

Aldo S Bader, Martin Bushell

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Aldo S BaderCancer Research UK Scotland Institute, Glasgow, UK. ab2510@cam.ac.uk.
Martin BushellCancer Research UK Scotland Institute, Glasgow, UK. martin.bushell@glasgow.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

DNA double-strand break (DSB)-induced mutagenesis is a critical contributor to a variety of human diseases; however, the ability to quantify these mutations is limited by the low sensitivity of current methodologies. Here we describe iMUT-seq, a technique that profiles DSB-induced mutations at high sensitivity and single-nucleotide resolution around endogenous DSBs, by coupling high-depth sequencing to restriction enzyme-inducible DSBs in human cell lines. iMUT-seq uses targeted sequencing to generate high-depth DNA libraries, enabling detection of mutations at incidence rates as low as 1 in 500,000. iMUT-seq can be used to identify novel mutagenic outcomes of DSBs and characterize previously unknown mechanisms of mutagenesis. The technique involves the extraction of genomic DNA from treated cells, followed by a multiplexed polymerase chain reaction and a series of library preparation reactions to generate a DNA library ready for sequencing on Illumina next-generation sequencing platforms. Finally, this novel approach to mutation profiling requires a specific analytical pipeline with careful considerations for the uncommon per-nucleotide nature of the data. Users will need experience in raw next-generation sequencing data analysis, and experience in DNA library preparation is beneficial. Overall, iMUT-seq has the potential to provide advanced insights into DSB mutagenesis, is a powerful tool in the study of novel DNA repair components and can be adapted to other organisms and types of DNA damage.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.